Literature DB >> 8313419

Effects of endothelins on collagen turnover in cardiac fibroblasts.

E Guarda1, L C Katwa, P R Myers, S C Tyagi, K T Weber.   

Abstract

OBJECTIVES: Endothelins (ET-1 and ET-3) may be promoters of tissue remodeling, including fibrillar collagen accumulation. The hypothesis that ET-1 and ET-3 each modify cardiac fibroblast collagen turnover was tested.
METHODS: Confluent adult rat cardiac fibroblasts were maintained for 24 hours in medium with 0.4% fetal calf serum, and varying concentrations of ET-1 or ET-3. Collagen synthesis was measured by 3H-proline incorporation. The synthesis of type I and III collagens was measured by enzyme linked immunosorbent assay (ELISA). The effects of endothelins on collagenase activity were estimated by zymography.
RESULTS: ET-1 and ET-3 increased collagen synthesis in a concentration-dependent manner with a maximal 1.7-fold increase (p < 0.001 v control cells). The effects of ET-1 or ET-3 on collagen synthesis were not blocked by PED-3512-PI (10(-6) M), an ETA receptor antagonist. ET-1 and ET-3 each significantly (p < 0.01) increased the synthesis of both type I and III collagens. ET-1 caused a 5.8-fold decrease in collagenase activity (p < 0.01 v control), and this effect was blocked by PED-3512-PI (10(-6) M). ET-3 did not alter collagenase activity.
CONCLUSION: ET-1 and ET-3 increased the synthesis of type I and III collagens, whereas ET-1, but not ET-3, reduced collagenase activity. The effects of endothelins on collagen synthesis in cardiac fibroblasts seem to be mediated through ETA and ETB receptors, whereas their effects on collagenase seem to be mediated by ETA receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8313419     DOI: 10.1093/cvr/27.12.2130

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  45 in total

Review 1.  Hemodynamic effects of bosentan in patients with chronic heart failure.

Authors:  W Kiowski; G Sütsch; E Oechslin; O Bertel
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 3.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

4.  Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

Authors:  P Paradis; N Dali-Youcef; F W Paradis; G Thibault; M Nemer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 5.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

6.  The role of the neurohormonal system in heart failure.

Authors:  M Komajda; F Pousset; R Isnard; P Lechat
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

7.  ENDOTHELIN-1 SYTEM ACTIVITY IN ADULTS WITH BORDERLINE HIGH LDL-CHOLESTEROL.

Authors:  Kyle J Diehl; Brian L Stauffer; Jared J Greiner; Christopher A DeSouza
Journal:  Artery Res       Date:  2014-09-01       Impact factor: 0.597

8.  Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo.

Authors:  Laxmansa C Katwa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

Review 9.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.